Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1984-05-24
1987-03-31
Phillips, Delbert R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
A61K 3523
Patent
active
046543252
ABSTRACT:
Novel medicaments and methods of use thereof are disclosed for reducing in a human or an animal nephrotoxic effects associated with positively charged molecules or agents. The positively charged molecules or agents may be endogenous or exogenous to the human or animal. Examples of endogenous positively charged molecules or agents include proteins or myoglobin, whereas exogenous positively charged molecules and agents may be pharmaceuticals, such as those derived from the aminoglycoside antibiotic family. The medicament comprises a positively charged (cationic) substance which is preferably substantially inert and substantially secreted by the proximal tubules of the kidney. An example of a positively charged (cationic) substance that is substantially inert is amprolium. In addition, the medicament may include a pharmaceutical, such as an aminoglycoside antibiotic for treating bacterial infection.
REFERENCES:
patent: 3900398 (1975-08-01), Gillette
patent: 4199570 (1980-04-01), Igarashi et al.
patent: 4200628 (1980-04-01), Igarashi et al.
patent: 4201774 (1980-05-01), Igarashi et al.
patent: 4226747 (1980-10-01), Ronchri
patent: 4248865 (1981-02-01), Igarashi et al.
patent: 4264766 (1981-04-01), Fischer
patent: 4273923 (1981-06-01), Igarashi et al.
patent: 4291692 (1981-09-01), Bowman et al.
patent: 4315907 (1982-02-01), Fridlender et al.
patent: 4323496 (1982-04-01), Mitani
patent: 4335114 (1982-06-01), Voss et al.
patent: 4362710 (1982-12-01), Watanabe
patent: 4393051 (1983-07-01), Stadler et al.
patent: 4423210 (1983-12-01), McAlpine et al.
patent: 4427662 (1984-01-01), Tadanier et al.
patent: 4430433 (1984-02-01), Hammond et al.
patent: 4457865 (1984-07-01), Miller
Polin, D. et al.: Amprolium 10. Influence of Egg Yolk Thiamine Concentration on Chick Embryo Mortality. Pro. Soc Exp. Bio. Med. vol. 110:844-846 (1962).
Besseghir, L. and Rennick, B. et al.: Renal Tubular Transport and Electrolyte Effects of Amiloride in the Chicken, Journal of Pharmacology and Experimental Therapeutics. vol. 219 (2):435-441 (1981).
Bennett, W. M. et al.: Effect of Basic Amino Acids in Aminoglycosides on .sup.3 H-Gentamicin Uptake in Cortical Slices of Rat and Human Kidney, Journal of Laboratory and Clinical Medicine, vol. 99 (2):156-162 (Feb. 1982).
Beyer, K. H. et al.: Functional Characteristics of the Renal Tubular Secretion of Amprolium, A Quaternary Organic Base, The Journal of Pharmacology and Experimental Therapeutics, vol. 195:pp. 194-200 (1975).
Polin, D. et al.: In Vivo Absorption of Amprolium and its Competition with Thiamine, Pro. Soc. Exp. Bio. Med. vol. 114:273-277 (1963).
Polin, D. et al.: Amprolim v. Studies in Laying Chickens and Their Eggs, Journal of Nutrition, vol. 76 (1):59-67 (Jan. 1962).
Bennett, W. M. et al.: Reduction of Experimental Gentamicin Nephrotoxicity in Rats by Dietary Calcium Loading, Antimicrobial Agents and Chemotherapy, vol. 22 (3):508-512 (1982).
Francke, E. et al.: Nephrotoxicity of Aminoglycosides, Infections in Surgery, (Mar. 1983).
LandOfFree
Medicament for reducing nephrotoxicity caused by positively char does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicament for reducing nephrotoxicity caused by positively char, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament for reducing nephrotoxicity caused by positively char will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2212964